Arbutus and Barinthus report preliminary Phase 2a data: imdusiran + VTP-300 sustains low HBsAg levels in cHBV

Arbutus Biopharma Corp

Preliminary data from AB-729-202 trial: 97% of imdusiran-treated pts had HBsAg <100 IU/mL at first VTP-300 dose.
Mean HBsAg reduction of -1.86 log10 after 24 weeks of imdusiran; all VTP-300 patients maintained <100 IU/mL through week 48.
60% of VTP-300 patients had HBsAg <10 IU/mL through week 48; all qualified to stop NA therapy.
HBV-specific T cell IFN-γ production enhanced vs placebo; no serious AEs, Grade 3/4 AEs, or discontinuations.
Updated corporate presentation posted on company website with additional pipeline details.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.